would be available for crop improvement selections. Toward this end, the authors targeted the promoter regions of two other genes with regulatory roles that influence productivity, COMPOUND INFLORESCENCE (controls flower proliferation) and SELF PRUNING (affects flowering time and hence the growth habit), for both of which there is little natural variation. They used their targeting approach to recover a collection of promoter alleles with varying effects on the phenotype. Different recovered alleles represented a continuum of effects on the respective phenotypes. The results illustrated the dosage sensitivity in both cases. Of course, not all genes involved with quantitative traits will necessarily be dosage sensitive, but a collection of heterozygous deletions in poplar (Henry et al., 2015) indicates the pervasive influence of dosage on the phenotype. Indeed, a collection of promoter mutations could be used to determine whether any particular gene shows this property. Nevertheless, the examples studied show how the dosage-sensitive property of regulatory genes can be used to advantage in breeding programs.
This proof of concept with tomato provides the concept to generate quantitative variation for crop improvement directly within elite lines that have already been selected for optimum production based on other criteria. Further, the authors suggest that it provides the ability to bring ''orphan crops'' with restricted production into wider use if their limitations can be overcome by editing. The world population relies on only three grass speciesmaize, wheat, and rice-for the majority of its calories, and a more diverse crop repertoire would help insure food security.
The examples studied were previously known quantitative trait genes for which a wide range of new alleles were generated. The question arises as to whether the technique can be extended to quantitative trait loci that have very weak effects and are not defined molecularly. Certainly, it seems possible that a reverse genetics approach on a gene known only by sequence could be subjected to the same process to recover a range of alleles that would be instructive as to its function and interaction with other genes. While the experimental organism in this proof of concept was tomato, the concept can be ecumenical for any species, including in the animal kingdom, to dissect quantitative traits and, in a more reductionist view, for examining regulatory networks on a basic level. 
Untangling the Web of Lymphoma Somatic Mutations
Matt Teater 1 and Ari Melnick 1, * In this issue of Cell, Reddy et al. report integrative genetic characterization of diffuse large B cell lymphomas (DLBCL), including large-scale exome capture, transcriptomes, CRISPR screens, and integrative clinical biomarker studies. This provides the first comprehensive overview of DLBCL biology and the basis for future precision medicine approaches to this disease.
Diffuse large B cell lymphomas (DLBCLs) are among the most genetically heterogeneous tumors and feature a characteristically high burden of somatic mutations (Chalmers et al., 2017) . Whereas initial sequencing studies yielded important insights into the classes of genes mutated in DLBCL, these earlier studies were not extensive enough to fully represent the spectrum of somatic mutations that define this tumor type. Fortunately, in this issue of Cell, Reddy et al. have set about the Herculean task of performing exome capture on 1,001 clinically annotated DLBCL cases and provide a virtual treasure chest of new information (Reddy et al., 2017) . Their study yields a truly comprehensive assessment of the DLBCL genetic landscape along with functional validation by CRISPR screening in DLBCL cell lines. Mutation detection analysis was based on 503 germline DNA-paired specimens, with the remainder serving as a validation and extension cohort. The authors identified 150 genes with recurrent somatic mutation in DLBCL, 27 of which had not been previously recognized as disease alleles in this tumor type.
One of the striking themes in DLBCL genetics is the frequent occurrence of somatic mutations in histone-modifying genes (Lohr et al., 2012; Morin et al., 2011; Pasqualucci et al., 2011) . This notion is confirmed and expanded on by Reddy et al. They observe as expected frequent mutations of KMT2D (MLL2), CREBBP, and EZH2. However, analysis of their data shows that mutations affecting transcription factors and epigenetic modifiers account for 36 of the 60 most recurrent lesions (affecting >5% of patients). Fully 85% of their patients have at least one of these types of mutations. 11 of these 60 highly recurrent genes are newly identified, and of these, 7 (SPEN, SETDB1, SMARCA4, MGA, ZNF608, ARID5B, ZNF292) are putative epigenetic modifiers or transcription factors. The most frequently affected of these is SPEN, which encodes a transcriptional repressor linked to NOTCH transcriptional complexes and other functions (VanderWielen et al., 2011) . Approximately 10% of patients manifested missense or frameshift/truncation mutations of this gene. The biological function of SPEN is unknown in mature B cells, and it is not clear which biological pathway is perturbed by these somatic mutations.
DLBCLs arise from fully mature B cells transiting the germinal center reaction and are not believed to derive from hematopoietic stem cells (HSCs). Yet somatic mutations in TET2 and DNMT3A, two tumor suppressors that occur as founder mutations in myeloid and T cell leukemias (Jaiswal et al., 2014) were also among the top 60 recurrent mutations detected. In the case of TET2, the SNVs seem consistent with the general theme of diffusely distributed mutations that may result in loss-of-function effects. Indeed, TET2 mutant DLBCLs were previously reported to manifest an aberrant DNA methylation signature (Asmar et al., 2013) . In the instance of DNMT3A, there were no cases of the canonical R882 mutation, characteristic of AML (acute myeloid leukemia) and MDS (myelodysplastic syndrome), and instead missense mutations mostly localized in the methyltransferase domain and known protein interaction surfaces were identified. It is unknown whether these DLBCL-related TET2 and DNMT3A somatic mutations are acquired during early hematopoiesis or later on in B cell development. But it is intriguing to speculate that DLBCL may inherit certain functionally relevant mutations from HSCs, as has been reported in other mature B cell and T cell neoplasm such as CLL (chronic lymphocytic leukemia) and AITL (angioimmunoblastic T cell lymphoma) (Damm et al., 2014; Lemonnier et al., 2012) .
To validate the function of identified mutations as putative oncogenes or tumor suppressors, Reddy et al. performed a genome-wide CRISPR screen covering 19,000 genes using the GeCKO.v2 human single guide (sgRNA) library. This is the first such screen reported in DLBCL and represents another valuable resource to the field. Prior functional screens using shRNA (small hairpin RNA) libraries have yielded important insights into specific vulnerabilities of DLBCL subtypes, and these are confirmed and expanded by this CRISPR approach. In this case, 1,900 genes were identified as essential for DLBCL cells. Genes represented by sgRNA that were depleted or enriched were statistically enriched for genes shown to be mutated by exome profiling. For example, MGA, ZNF608, and NCOR1 were all validated as putative tumor suppressors, whereas PAX5, YY1, HIST1HIE, and POU2F2 were validated as oncoproteins. A number of mutated genes confirmed by CRISPR are known therapeutic targets with existing drugs (e.g., MCL1, BTK, XPO1) and were again validated in this study as potential important targets in dose-response experiments. Overall, there was a generally consistent theme between somatic mutation, CRISPR screen, and experimental therapeutics testing across the board, confirming the significance of identified somatic mutations for the biology and precision therapy of DLBCL.
In addition to exome sequencing, the authors also carried out RNA-seq (RNA sequencing) in a majority of their DLBCL cases. They were able to accurately classify the lymphomas according to activated B cell-like (ABC) and germinal center B cell-like (GCB) subtypes. Gene expression profiles were used in several interesting ways including associating specific mutations to known gene sets or pathways. Some of these are expected, such as mutation of CCND3 or CDKN2A associating with DNA replication or TP53 with DNA damage signatures. However, others suggest novel pathways of potential major interest. For example, the newly discovered somatic mutations in the Kelch-like and likely ubiquitylation-related gene KLHL14 were significantly enriched in an MYC signature, suggesting a potential link between these two proteins that needs to be explored.
The fact that these patients were clinically annotated allowed the authors to examine associations between mutations, gene expression, and clinical outcomes. They confirmed inferior outcome for ABC DLBCLs and patients with genetic alterations in MYC but also identified many new associations between genetics and outcome. For example, mutations in PAX5, KLHL14, and BTG1 were all linked to inferior survival in a univariate analysis of ABC-DLBCLs. A more sophisticated multivariate model integrating cell of origin, gene expression, and genetic lesions confirmed KLHL14 in ABC-DLBCLs as linked to higher clinical risk, along with several other putative combinations, which is intriguing given the suggested link between KLHL14 and MYC. Collectively, this massive effort to sequence exomes and transcriptomes and perform genome-wide functional and therapeutic validation all adds up to a highly valuable and important resource characterizing one of the more genetically complex tumor types for which large-scale studies have not been previously available. This new roadmap for DLBCL genetics will serve as a cornerstone for future mechanistic, biomarker, and therapeutic studies, for example prioritizing drugs and combinations for the design of precision medicine clinical trials.
